Today
Where to start today.
Clinic of the day
Eternami
Singapore · Singapore
Be the first to save this
Company watch
Mirxes Holding Company Limited
HKEX · HKEX:2629
Fund watch
Square Peg Capital
VC · ~A$2.9B
Protocol primer
Growth hormone secretagogues: CJC-1295 and ipamorelin
Mechanism5 sources
Person spotlight
Lindsay Cooper
Chi Longevity
Linked to 1 organisation
What to watch
No confirmed events in the near term. The calendar tracks every dated move.
More coverage
The rest of today’s briefing.
Regulatory · Global
FDA approves oral semaglutide (Wegovy)
6 DecGlobal
Insilico Medicine lists on the Hong Kong Stock Exchange
30 DecSingapore + Australia · Capital
Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026
29 JunAustralia
Everlab closes an AU$65M Series A
16 JunTrial milestone · Singapore
PROMETHEUS advances to the XPRIZE Healthspan finals
15 AprGlobal · Protocol
GLP-1s and healthspan: a 2026 reader’s primer
1 JulSingapore · Clinical
New trial to test precision geromedicine for healthy ageing
1 JulSingapore · Industry
NUS launches healthy longevity graduate certificate
1 JulSingapore · Industry
Can longevity be designed for everyone, not just the wealthy?
1 JulRegulatory · Global
FDA approves oral orforglipron (Foundayo)
1 AprCoverage
Science and lifestyle
Coverage
Capital and public markets
Coverage
Industry and regulation
Markets
38 tracked- Insilico MedicineHKEX · HKEX:3696
IPO 30 Dec 2025, largest 2025 HK biotech IPO; Temasek cornerstone.
Last move: 30 Dec
- Nuevocor Pte Ltd
On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news).
Every claim traced to a named source and evidence-graded. See how at editorial standards, or the public corrections log.